Breaking News
23 hours ago
Vaibhavi M.

Sanofi's Sarclisa SC gains Japan approval for multiple myeloma; CirCLIQ on-body injector application remains under review.
Vaibhavi M.

3PBIOVIAN's AAVion® platform targets CMC compliance and cost-of-goods risks in AAV gene therapy manufacturing amid rising regulatory scrutiny.
Vaibhavi M.

3PBIOVIAN identifies documentation gaps and scale-up failures as the leading causes of GMP delays in recombinant protein programs ahead of IND filing.
Vaibhavi M.

Axcelead presents a multi-cell-line proteomics platform for TPD off-target safety assessment at JSOT 2026, detecting ~10,000 proteins across a human-derived panel.
Simantini Singh Deo
